November 12th 2024
A 12-week regimen showed significant reductions in wrinkle severity and pigment improvement.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Novel compound shows early promise for treatment of acne
November 1st 2005The retinoic acid metabolism-blocking agent (RAMBA) Rambazole (Barrier Therapeutics) has demonstrated promising efficacy and safety as a novel oral treatment for acne in early clinical trials along with potential activity as a topically applied agent. Based on those results, this novel compound is about to proceed into further testing of its topical use in a multicenter, randomized, double-blind, vehicle-controlled study and for oral administration in a double–blind, dose-finding study.
New phototherapy approach restores pigment, quality of life
November 1st 2005Walnut Creek, Calif. — Advances in phototherapy are bringing greatly needed new options for the treatment of hypopigmentary conditions in patients with ethnic skin, says Min-Wei Christine Lee, M.D., M.P.H., a dermatologic surgeon and director, The East Bay Laser and Skin Care Center, Walnut Creek, Calif.
Solar lentigines amenable to multiple treatment options
November 1st 2005Atlanta — There is a spectrum of modalities available for clearing solar lentigines, but management of those pigmented lesions should be individualized based on patient-related factors and be integrated into a general skincare program that simultaneously addresses comorbid features of photoaging and prevents future damage, says Jonathan S. Weiss, M.D., assistant clinical professor of dermatology, Emory University School of Medicine, here.
Prevent, reverse structural degradation of skin
November 1st 2005National report — Prevention of photoaging is the ultimate approach to a growing problem, yet a population persists in which more than 90 percent of actinic damage can be attributed to long-term sun exposure. The use of non-invasive methods, often preferred by patients, can reverse the obvious signs of aging.
Case series experience suggests expanding role for topical imiquimod
November 1st 2005National report — Accumulating data is adding evidence to support a role for topical imiquimod 5 percent cream (Aldara, 3M Pharmaceuticals) as a secondary alternative to conventional excisional or Mohs micrographic surgery for treating various types of skin cancers in patients who are poor surgical candidates — or refuse surgery — says M. Shane Chapman, M.D., assistant professor of dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, N.H.
Hairline design in hair restoration surgery
November 1st 2005For hair transplants to be successful in the long-term, it is critical to consider that patients are limited by the amount of good genetichair that can be transferred to the balding area, and the establishment of the hairline will ultimately dictate the amount of balding scalp that willeventually need to be covered.
Alternative to Botox for underarm sweating
November 1st 2005Palm Desert, Calif. — As an alternative to the increasingly popular option of using botulinum toxin type A (Botox, Allergan) to treat excessive underarm sweating, some patients are experimenting with undergoing surgery that they report to be more lasting.
Study shows ointments appear worthless for wound healing
November 1st 2005Atlanta — According to a recent study, placing ointment on surgical wounds before applying occlusive dressings provides no observable benefits; moreover, applying mupirocin ointment to clean surgical wounds is contraindicated given the potential for creating antibiotic resistance.